Asia Pacific Clinical Trial Imaging Market Forecast to 2028 -Regional Analysis - by Modality [Tomography, Magnetic Resonance Imaging (MRI), Ultrasound, Positron Emission Tomography (PET), X-Ray, Echocardiography, and Others], Offering (Operational Imaging

Asia Pacific Clinical Trial Imaging Market Forecast to 2028-Regional Analysis- by Modality [Tomography, Magnetic Resonance Imaging (MRI), Ultrasound, Positron Emission Tomography (PET), X-Ray, Echocardiography, and Others], Offering (Operational Imaging Services, Imaging Software, Read Analysis Services, Trial Design and Consulting Services, and Others), and End User [Contract Research Organizations (CROs), Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others]

The Asia Pacific clinical trial imaging market is expected to grow from US$ 373.46 million in 2023 to US$ 553.11 million by 2028; it is estimated to register a CAGR of 8.2% from 2023 to 2028.

AI-Driven Clinical Trials to Fuel Asia Pacific Clinical Trial Imaging Market During Forecast Period

Artificial Intelligence (AI) aids in effective data collection and management and, thus, acts as a game changer for life science companies involved in the drug development process. The adoption of AI drives innovative ways of collecting clinical trial data and reducing dependency on manual operations. This can be well illustrated by the following used case: AstraZeneca has collected oncology data, including clinical and imaging data, of more than 100,000 consenting patients for different clinical studies. To transform the process of oncology data feed, the team adopts complex datasets for accessibility, interoperability, and reusability of data through FAIR. Such integration allows the collected data from specific clinical trials and projects to be accessible across the company's drug development teams, in compliance with data protection laws. Further, AstraZeneca is working with external companies such as Tempus to leverage real-world data and represent patients across the region. Such strategic partnerships/inorganic strategies offer crucial evidence about patient outcomes in a healthcare system without revealing the identity of the clinical trial participants in the datasets. Thus, the increasing application of AI for processing clinical trial data is likely to catalyze the growth of the Asia Pacific clinical trial imaging market in the coming years.

Asia Pacific Clinical Trial Imaging Market Overview

The Asia Pacific clinical trial imaging market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held the largest share in the market in 2022, and it is expected to register the highest CAGR of 8.6% during the forecast period. The growth is due to the established pharmaceutical, a rise in R&D expenditure by the pharmaceutical and biopharmaceutical companies, a surge in clinical trials due to lower cost, well-established healthcare technologies, the launch of innovative products by key players, and favorable regulatory policies. China has the world’s second-largest pharmaceutical market. The excessive population in China, coupled with the rise of various communicable and noncommunicable diseases, is majorly driving the growth of pharmaceutical companies in China.

Asia Pacific Clinical Trial Imaging Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Clinical Trial Imaging Market Segmentation

The Asia Pacific clinical trial imaging market is segmented on the basis of modality, offering, end user, and country.

Based on modality, the Asia Pacific clinical trial imaging market is segmented into tomography, magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), X-ray, echocardiography, and others. The tomography segment registered the largest market share in 2023.

Based on offering, the Asia Pacific clinical trial imaging market is segmented into operational imaging services, imaging software, read analysis services, trial design and consulting services, and others. The operational imaging services segment held the largest market share in 2023.

Based on end user, the Asia Pacific clinical trial imaging market is segmented into contract research organizations (CROs), pharmaceutical and biotechnology companies, academic and research institutes, and others. The contract research organizations (CROs) segment held the largest market share in 2023.

Based on country, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market share in 2023.

Calyx Inc, eResearch Technology Inc, ICON PLC, IXICO plc, Medical Metrics Inc, Radiant Sage LLC, VIDA Diagnostics Inc, and WCG Clinical Inc are the leading companies operating in the Asia Pacific clinical trial imaging market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific clinical trial imaging market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific clinical trial imaging market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the clinical trial imaging market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution